Bullish on Agios
-Company waiting Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation from the FDA (Due early August).
-Thier IDH1m (IVOSIDENIB) looks somewhat promising
- They are currently at 53.84 which is low given the above two points.
AGIO
-Thier IDH1m (IVOSIDENIB) looks somewhat promising
- They are currently at 53.84 which is low given the above two points.
AGIO
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.